Antiproliferative and anti-invasive effects of inorganic and organic arsenic compounds on human and murine melanoma cells in vitro

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 9, 2011, Pages 1202-1210

  Hiwatashi, Yoko ^a,b   Tadokoro, Hiroko ^a   Henmi, Kayo ^a   Arai, Mariko ^b   Kaise, Toshikazu ^a   Tanaka, Sachiko ^a   Hirano, Toshihiko ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b KITASATO UNIVERSITY HOSPITAL   (Japan)

Author keywords

arsenic compounds; cell invasion; collagen matrix; matrix metalloproteinase; melanoma cells

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ARSENIC ACID; ARSENIC DERIVATIVE; ARSENIC TRIOXIDE; ARSENOBETAINE; ARSENOCHOLINE; BROXURIDINE; CACODYLIC ACID; COLLAGEN TYPE 4; GELATINASE A; INORGANOARSENIC DERIVATIVE; METHANEARSONIC ACID; ORGANOARSENIC DERIVATIVE; TETRAMETHYLARSONIUM; TRIMETHYLARSINE OXIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL INVASION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME RELEASE; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INCUBATION TIME; MELANOMA; MELANOMA CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; ARSENIC; ARSENICALS; CELL LINE, TUMOR; CELL PROLIFERATION; COLLAGEN TYPE IV; HUMANS; MATRIX METALLOPROTEINASE 2; MELANOMA; MICE; NEOPLASM INVASIVENESS;

EID: 80051681318     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01330.x     Document Type: Article

References (34)

1. Serrone L, et al,. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000; 19: 21-34. (Pubitemid 30305516)
2. Rubin KM, Lawrence DP,. Your patient with melanoma: staging, prognosis, and treatment. Oncology (Huntingt) 2009; 23 (Suppl.): 13-21.
3. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-3360.
4. Niu BC, et al,. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315-3324.
5. Soignet SL, et al,. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852-3860. (Pubitemid 32880064)
6. 3 exerts dose- dependent dual effects on APL cells. Blood 1997; 89: 3345-3353.
7. Kinjo K, et al,. Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice. Leukemia 2000; 14: 431-438. (Pubitemid 30142867)
8. Wang ZG, et al,. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RAR alpha independent manner. Blood 1998; 92: 1497-1504.
9. Zhang W, et al,. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia 1998; 12: 1383-1391. (Pubitemid 28442384)
10. Perkin C, et al,. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x (L). Blood 2000; 95: 1014-1022.
11. Akao Y, et al,. Arsenic-induced apoptosis in malignant cells in vitro. Leuk Lymphoma 2000; 37: 53-63. (Pubitemid 30142579)
12. Hu X-M, et al,. Arsenic trioxide induces apoptosis in MOLT-4 and its daunorubicin-resistant MOLT-4 cell lines via depletion of intracellular glutathione, disruption of mitochondrial membrane potential and activation of caspase-3. Cancer Chemother Pharmacol 2003; 52: 47-58. (Pubitemid 36920628)
13. Ralph SJ,. Arsenic-based antineoplastic drugs and their mechanisms of action. Met Based Drugs 2008; ID260146.
14. Wang C, et al,. Effect of arsenic trioxide on uveal melanoma cell proliferation in vitro. Ophthalmic Res 2007; 39: 302-307. (Pubitemid 350242709)
15. Bael TE, et al,. Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases. Melanoma Res 2008; 18: 147-151. (Pubitemid 351398270)
16. Tarhini AA, et al,. Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma. Cancer 2008; 112: 1131-1138. (Pubitemid 351304599)
17. Henmi K, et al,. Methoxy- and fluoro-chalcone derivatives arrest cell cycle progression and induce apoptosis in human melanoma cell A375. Biol Pharm Bull 2009; 32: 1109-1113.
18. Porstmann T, et al,. Quantitation of 5-bromo-2-deoxyuridine incorporation into DNA: an enzyme immunoassay for the assessment of the lymphoid cell proliferative response. J Immunol Methods 1985; 82: 169-179. (Pubitemid 16253231)
19. Braman RS, Foreback CC,. Methylated forms of arsenic in the environment. Science 1973; 182: 1247-1249.
20. Crecelius EA,. Changes in the chemical speciation of arsenic following ingestion by man. Environ Health Perspect 1977; 19: 147-150. (Pubitemid 8182691)
21. Fok JY, et al,. Implications of tissue transglutaminase expression in malignant melanoma. Mol Cancer Ther 2006; 5: 1493-1503.
22. 3 induces NB4 cell apoptosis with down regulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996; 88: 1052-1061.
23. Baumgartner M, et al,. Enhancement of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxide-resistant solid tumor cells. Int J Cancer 2004; 112: 707-712. (Pubitemid 39425954)
24. Dai J, et al,. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999; 93: 268-277. (Pubitemid 29019412)
25. Jutooru I, et al,. Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growth. Exp Cell Res 2010; 316: 2174-2188.
26. Marchesi F, et al,. Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res 2007; 56: 275-287. (Pubitemid 47488901)
27. Yu J, et al,. Arsenic trioxide (As2O3) reduces the invasive and metastatic properties of cervical cancer cells in vitro and in vivo. Gynecol Oncol 2007; 106: 400-406. (Pubitemid 47096659)
28. Zhang J, Wang B,. Arsenic trioxide (As(2)O(3)) inhibits peritoneal invasion of ovarian carcinoma cells in vitro and in vivo. Gynecol Oncol 2006; 103: 199-206. (Pubitemid 44374690)
29. Park MJ, et al,. Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species. J Cell Biochem 2005; 95: 955-969.
30. Arnaoutova I, et al,. The endothelial cell tube formation assay on basement membrane turns 20: state of the science and the art. Angiogenesis 2009; 12: 267-274.
31. Menon LG, et al,. Anti-metastatic activity of curcumin and catechin. Cancer Lett 1999; 141: 159-165. (Pubitemid 29261735)
32. Bazan-Socha S, et al,. Increased expression of collagen receptors: alpha1beta1 and alpha2beta1 integrins on blood eosinophils in bronchial asthma. Clin Exp Allergy 2006; 36: 1184-1191. (Pubitemid 44342934)
33. Staniszewska I, et al,. Effect of VP12 and viperistatin on inhibition of collagen-receptor-dependent melanoma metastasis. Cancer Biol Ther 2009; 8: 1507-1516.
34. Redondo P, et al,. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression. Clin Exp Dermatol 2005; 30: 541-545. (Pubitemid 41076024)